A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Daprodustat (Primary) ; Ferrous sulfate; Recombinant erythropoietin
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 28 Jun 2018 Planned End Date changed from 27 Mar 2019 to 6 May 2019.
- 28 Jun 2018 Planned primary completion date changed from 27 Mar 2019 to 6 May 2019.
- 28 Jun 2018 Planned initiation date changed from 22 Jun 2018 to 1 Aug 2018.